|
|
|
|
|
Louis G. Lange, M.D., Ph.D.
|
|
|
Chairman of the Board, Metabolex; Senior Advisor-
Gilead Sciences; Former Chairman, Chief Executive
Officer and Chief Science Officer, CV
Therapeutics, Inc.
|
|
|
|
Dr. Lange has 22 years' experience in academic
medicine at Harvard University and Washington
University, where he served as Chief of
Cardiology and Professor of Medicine at Jewish
Hospital from 1985-1992 and was one of the first
academicians in molecular cardiology. Most
recently, Dr. Lange founded CV Therapeutics, Inc.
in 1992, where he served as Chairman, CEO and
Chief Scientific Officer, overseeing the
successful commercialization of a product
portfolio solely focused on cardiovascular
health. Dr. Lange led the company's success
through its sale in 2009 to Gilead Sciences. Dr.
Lange has served as a trustee on the University
of Rochester Board of Trustees since 1998 and
from 1999 to 2009 he served on the Biotechnology
Industry Organization (BIO) Board of Directors.
In addition, he is on the Board of Directors of
the Institute for Systems Biology in Seattle, WA;
is the Chairman of the Board of CardioDX and also
sits on the Boards of Maxygen and Synecor. Dr.
Lange holds an M.D. from Harvard Medical School
and a Ph.D. in biochemistry from Harvard
University.
Top
|
|
|
|
|
|
Bradley Bolzon, Ph.D.
|
|
|
Managing Director, Versant Ventures
|
|
|
|
Dr. Bolzon currently is a Managing Director of
Versant Ventures, a venture capital firm
specializing in early stage Biotech investments.
Prior to joining Versant, he served as Executive
Vice President at F. Hoffmann-La Roche Ltd.,
where he directed business development strategy,
product licensing, company acquisitions, and
R&D alliances. Previously, Dr. Bolzon held
executive roles at Eli Lilly and Company. He
currently serves as a board member for Anaphore,
Inc., Flexion Therapeutics, and serves as
Chairman of the Board of Synosia Therapeutics and
Amira Pharmaceuticals. Dr. Bolzon is also
Chairman of EuroVentures Inc., a wholly-owned
start-up incubator of Versant Ventures. He
received Ph.D. and M.S. degrees in Pharmacology
from the University of Toronto, and conducted his
post-doctoral research training at the Ottawa
Heart Institute in Ottawa, Canada.
Top
|
|
|
|
|
|
Anthony B. Evnin, Ph.D.
|
|
|
General Partner, Venrock
|
|
|
|
Dr. Evnin joined Venrock in 1974 and built the
firm's healthcare franchise, helping to shape the
modern biotechnology industry. He started his
career as a research scientist at Union Carbide
and as director of product development at Story
Chemical. More than 29 of his investments have
been through an initial public offering during
his Venrock tenure. Dr. Evnin serves as a Trustee
Emeritus of Princeton University and as a trustee
of The Rockefeller University. Dr. Evnin is
focused on building valuable companies that
address important medical needs of the world,
while providing strong returns for investors. Dr.
Evnin currently is the Chairman of the Board of
Boston Power and serves on the boards of
Acceleron Pharma, Altea Therapeutics, AVEO
Pharmaceuticals, Celladon, Constellation
Pharmaceuticals, Icagen, Infinity
Pharmaceuticals, and Pharmos Corporation, all
Venrock investments.
Top
|
|
|
|
|
|
Carl Goldfischer, M.D.
|
|
|
Managing Director, Bay City Capital
|
|
|
|
Dr. Goldfischer is an investment partner and
managing director of Bay City Capital, serving as
a member of the board of directors and executive
committee, and has been with the firm since
December 2000. His background includes extensive
public and private investment and transaction
work, as well as clinical trial development
knowledge. Prior to joining Bay City Capital, Dr.
Goldfischer was chief financial officer of
ImClone Systems. Previously, he was a research
analyst with the Reliance Insurance Company,
helping to establish its portfolio and presence
in the health care investment community. Dr.
Goldfischer is a member of the board of directors
for BrainCells, EnteroMedics, Epizyme, MAP
Pharmaceuticals, Poniard Pharmaceuticals, and PTC
Therapeutics. He is also a member of the board of
trustees of Mt. Zion Hospital. Dr. Goldfischer
received an M.D. with honors in scientific
research from Albert Einstein College of Medicine
and a B.A. from Sarah Lawrence College.
Top
|
|
|
|
|
|
Edward Penhoet, Ph.D.
|
|
|
Director, Alta Partners
|
|
|
|
Dr. Penhoet is past president of the Gordon and
Betty Moore Foundation, and currently a member of
the Board of Trustees. Prior to his work there,
Dr. Penhoet served as the dean of the School of
Public Health at the University of California,
Berkeley. In 1981, he co-founded Chiron
Corporation and served as its Chief Executive
Officer until 1998. Dr. Penhoet sits on the
boards of ChemoCentryx, Chimerix, Immune Design,
Scynexis, and ZymoGenetics. He is a member of the
Institute of Medicine of the National Academies
and has co-authored more than 50 scientific
articles and papers. Dr. Penhoet currently serves
as the Vice Chairman of the Independent Citizen's
Oversight Committee which oversees the California
Institute for Regenerative Medicine created by
the passage of Proposition 71, the stem cell
initiative. Dr. Penhoet earned his A.B. in
biology from Stanford University and his Ph.D. in
biochemistry from the University of Washington.
He was a post-doctoral fellow at the University
of California, San Diego.
Top
|
|
|
|
|
|
Daan A. van den Noort, M.D.
|
|
|
Chief Investment Officer, BTF
|
|
|
|
Dr. van den Noort joined BTF full-time as Chief
Investment Officer in 2002 and had been a member
of the company's business advisory board of BTF
since it was founded. Before joining BTF, he was
general manager at Ferring Drugs, a
privately-owned pharmaceutical company in
Denmark, where he specialized in the marketing
and product development of pharmaceuticals. Dr.
van den Noort has been product manager at Servier
France in Paris and The Netherlands, as well as a
marketing manager at Kabi Pharmacia Nederland,
managing director at Genentech Nederland and
general manager at Pharma Asta Medica Nederland.
He obtained his medical degree at the Vrije
Universiteit in Amsterdam.
Top
|
|
|
|
|
|
Harold E. Van Wart, Ph.D.
|
|
|
President and Chief Executive Officer, Metabolex,
Inc.
|
|
|
Dr. Van Wart currently serves as Metabolex,
Inc.'s Chief Executive Officer, a member of the
Board of Directors since January 2003, and
President since April 2001. He served as chief
operating officer from December 2002 to January
2003 and senior vice president, research and
development from October 2000 to December 2002.
From 1999 to 2000, Dr. Van Wart was vice
president and therapy head for arthritis and
fibrotic diseases at Roche Biosciences, a
biopharmaceutical company. From 1992 to 1999, he
was vice president and director of the institute
of biochemistry and cell biology at Syntex
Corporation, a biopharmaceutical company acquired
by Roche Biosciences in 1994. From 1978 to 1992,
Dr. Van Wart served on the faculty of Florida
State University. Dr. Van Wart obtained his Ph.D.
from Cornell University. He currently serves on
the Emerging Companies and Health Section
Governing Boards of the Biotechnology Industry
Organization, as well as on its Board of
Directors. He is also a Director of Conatus
Pharmaceuticals, Inc.
Top
|
|
|
|
|
Kurt von Emster
|
|
|
Managing Director, venBio
|
|
|
|
Mr. von Emster currently serves as a
Managing Director of venBio. From November 2000
to March 2009, Mr. von Emster was
Managing Director of MPM BioEquities and a
Portfolio Manager for the MPM BioEquities Fund.
From July 1989 to November 2000, Mr. von
Emster was with the Franklin Templeton
Group, most recently as a Vice President and
Portfolio Manager. Mr. von Emster is
currently a member of the board of directors at
Somaxon Pharmaceuticals, Inc., and Facet Biotech,
both public biotechnology companies. Mr.
von Emster is a Chartered Financial
Analyst (CFA), a member of the Association for
Investment Management and Research and of the
Security Analysts of San Francisco. Mr. von
Emster received his B.S. degree from the
University of California at Santa Barbara.
Top
|
|
|
|
|
Robert Zerbe, M.D.
|
|
|
Chief Executive Officer, QuatRx Pharmaceuticals
|
|
|
|
Dr. Zerbe is the Chief Executive Officer,
Director and co-founder of QuatRx
Pharmaceuticals, Inc. Dr. Zerbe has extensive
experience in global clinical development and
regulatory affairs. From 1982 to 2000, he held
a variety of research and development
positions, including managing director, Lilly
Research Center U.K., senior vice president of
worldwide clinical research and development at
Parke Davis, and senior vice president for
Pfizer global research and development. Dr.
Zerbe earned his medical degree at Indiana
University in 1975, and completed his
post-doctoral work in internal medicine,
endocrinology, and neuroendocrinology at
Indiana and the National Institutes of Health.
Dr. Zerbe currently serves on the boards of AP
Pharma, Aastrom Biosciences, Anesiva
Pharmaceuticals, and the Biotechnology Industry
Organization Emerging Section Governing Body.
Top
|
|
|
|
